Cowen Maintains Outperform On Shares Of Idera Following Recent Events
In a research report sent to investors today, Cowen analyst Boris Peaker maintained an Outperform rating on Idera (NASDAQ:IDRA), while no price target was provided.
Peaker noted, “Idera presented preclinical data for IMO-2055 yesterday at the AACR Tumor Immunotherapy meeting and announced the appointment of a new CEO (Vincent Milano) earlier in the week. IDRA’s rare disease program became a little more focused over the last few months and we believe with Milano the programs should become well-defined during 2015. We remain focused on IMO-8400 safety data in 2015 and maintain our Outperform rating.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Boris Peaker has a total average return of 30.3% and a 65.0% success rate. Peaker has a 48.2% average return when recommending IDRA, and is ranked #88 out of 3393 analysts.